JP2022539648A - 無煙たばこ製品におけるイソチオシアネートの使用 - Google Patents
無煙たばこ製品におけるイソチオシアネートの使用 Download PDFInfo
- Publication number
- JP2022539648A JP2022539648A JP2021566938A JP2021566938A JP2022539648A JP 2022539648 A JP2022539648 A JP 2022539648A JP 2021566938 A JP2021566938 A JP 2021566938A JP 2021566938 A JP2021566938 A JP 2021566938A JP 2022539648 A JP2022539648 A JP 2022539648A
- Authority
- JP
- Japan
- Prior art keywords
- isothiocyanate
- tobacco
- product
- ingestible
- ingestible product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002540 isothiocyanates Chemical class 0.000 title claims abstract description 66
- 235000019505 tobacco product Nutrition 0.000 title abstract description 10
- KEQHJBNSCLWCAE-UHFFFAOYSA-N thymoquinone Chemical compound CC(C)C1=CC(=O)C(C)=CC1=O KEQHJBNSCLWCAE-UHFFFAOYSA-N 0.000 claims abstract description 76
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 46
- 241000208125 Nicotiana Species 0.000 claims abstract description 45
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims abstract description 45
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 36
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 35
- 229940016667 resveratrol Drugs 0.000 claims abstract description 35
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 25
- 229960002715 nicotine Drugs 0.000 claims abstract description 25
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 25
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 23
- 239000002243 precursor Substances 0.000 claims abstract description 23
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 23
- 239000011718 vitamin C Substances 0.000 claims abstract description 23
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 108010058651 thioglucosidase Proteins 0.000 claims abstract description 19
- 239000000284 extract Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 19
- 235000017879 Nasturtium officinale Nutrition 0.000 claims description 16
- 240000005407 Nasturtium officinale Species 0.000 claims description 16
- 244000211187 Lepidium sativum Species 0.000 claims description 15
- 235000007849 Lepidium sativum Nutrition 0.000 claims description 15
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 claims description 12
- 235000019508 mustard seed Nutrition 0.000 claims description 11
- 235000016720 allyl isothiocyanate Nutrition 0.000 claims description 6
- 235000019504 cigarettes Nutrition 0.000 claims description 6
- 230000001055 chewing effect Effects 0.000 claims description 5
- 235000019506 cigar Nutrition 0.000 claims description 5
- 239000000693 micelle Substances 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 229940055329 tobacco leaf extract Drugs 0.000 claims description 4
- 244000090896 Nigella sativa Species 0.000 claims description 3
- 235000016698 Nigella sativa Nutrition 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims 2
- IZJDOKYDEWTZSO-UHFFFAOYSA-N phenethyl isothiocyanate Chemical compound S=C=NCCC1=CC=CC=C1 IZJDOKYDEWTZSO-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 38
- 229940117953 phenylisothiocyanate Drugs 0.000 description 19
- 230000006907 apoptotic process Effects 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000000391 smoking effect Effects 0.000 description 12
- -1 allyl ITC Chemical class 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 230000030833 cell death Effects 0.000 description 10
- 238000002073 fluorescence micrograph Methods 0.000 description 10
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 239000000779 smoke Substances 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 230000004611 cancer cell death Effects 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000047934 Caspase-3/7 Human genes 0.000 description 3
- 108700037887 Caspase-3/7 Proteins 0.000 description 3
- 206010057852 Nicotine dependence Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 2
- JMEVHYCNAPFOAB-UHFFFAOYSA-N 2-(3-hydroxy-5-sulfo-1H-indol-2-yl)-3-oxoindole-5-sulfonic acid Chemical compound Oc1c([nH]c2ccc(cc12)S(O)(=O)=O)C1=Nc2ccc(cc2C1=O)S(O)(=O)=O JMEVHYCNAPFOAB-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- PHZOWSSBXJXFOR-MYMDCHNCSA-N Sinigrin Natural products S(=O)(=O)(O/N=C(\S[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)/CC=C)O PHZOWSSBXJXFOR-MYMDCHNCSA-N 0.000 description 2
- 208000025569 Tobacco Use disease Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- QQGLQYQXUKHWPX-RFEZBLSLSA-N glucotropeolin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1S\C(=N/OS(O)(=O)=O)CC1=CC=CC=C1 QQGLQYQXUKHWPX-RFEZBLSLSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 235000012738 indigotine Nutrition 0.000 description 2
- 239000004179 indigotine Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000032896 mitotic cell cycle arrest Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000010215 titanium dioxide Nutrition 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- CKIJIGYDFNXSET-GVGPGJNLSA-N 2-Phenylethylglucosinolate Natural products S(=O)(=O)(O/N=C(/S[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)\CCc1ccccc1)O CKIJIGYDFNXSET-GVGPGJNLSA-N 0.000 description 1
- PHZOWSSBXJXFOR-UHFFFAOYSA-N 2-Propenyl glucosinolate Natural products OCC1OC(SC(CC=C)=NOS(O)(=O)=O)C(O)C(O)C1O PHZOWSSBXJXFOR-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- 235000007129 Cuminum cyminum Nutrition 0.000 description 1
- 108010060385 Cyclin B1 Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- ZPFWVYNZDHOONR-UHFFFAOYSA-N Ethyl glucosinolate Natural products OS(=O)(=O)ON=C(CC)SC1OC(CO)C(O)C(O)C1O ZPFWVYNZDHOONR-UHFFFAOYSA-N 0.000 description 1
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- ZPFWVYNZDHOONR-PHGZAPERSA-N Glucolepidiin Natural products S(=O)(=O)(O/N=C(/S[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)\CC)O ZPFWVYNZDHOONR-PHGZAPERSA-N 0.000 description 1
- MREWWWLAQJZJKR-RGDJUOJXSA-N Gluconasturtiin Natural products OC[C@H]1O[C@@H](SC(=NCCc2ccccc2)OS(=O)(=O)O)[C@H](O)[C@@H](O)[C@@H]1O MREWWWLAQJZJKR-RGDJUOJXSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UWSDONTXWQOZFN-UHFFFAOYSA-N N-nitrosopiperidine Chemical compound O=NN1CCCCC1 UWSDONTXWQOZFN-UHFFFAOYSA-N 0.000 description 1
- 229910000503 Na-aluminosilicate Inorganic materials 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004111 Potassium silicate Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000012741 allura red AC Nutrition 0.000 description 1
- 239000004191 allura red AC Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- IDZYHGDLWGVHQM-UHFFFAOYSA-N aluminum;calcium;sodium;silicate Chemical compound [Na+].[Al+3].[Ca+2].[O-][Si]([O-])([O-])[O-] IDZYHGDLWGVHQM-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229960003920 ***e Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- BCAARMUWIRURQS-UHFFFAOYSA-N dicalcium;oxocalcium;silicate Chemical compound [Ca+2].[Ca+2].[Ca]=O.[O-][Si]([O-])([O-])[O-] BCAARMUWIRURQS-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- ZPFWVYNZDHOONR-XLKLPJSCSA-N glucolepidiin Chemical compound CC\C(S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)=N\OS(O)(=O)=O ZPFWVYNZDHOONR-XLKLPJSCSA-N 0.000 description 1
- CKIJIGYDFNXSET-MFIRQCQASA-N gluconasturtiin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1S\C(=N\OS(O)(=O)=O)CCC1=CC=CC=C1 CKIJIGYDFNXSET-MFIRQCQASA-N 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 238000002670 nicotine replacement therapy Methods 0.000 description 1
- 239000001711 nigella sativa Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- NNHHDJVEYQHLHG-UHFFFAOYSA-N potassium silicate Chemical compound [K+].[K+].[O-][Si]([O-])=O NNHHDJVEYQHLHG-UHFFFAOYSA-N 0.000 description 1
- 229910052913 potassium silicate Inorganic materials 0.000 description 1
- QKFAFSGJTMHRRY-OCFLFPRFSA-M potassium;[(e)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylbut-3-enylideneamino] sulfate Chemical compound [K+].OC[C@H]1O[C@@H](S\C(CC=C)=N\OS([O-])(=O)=O)[C@H](O)[C@@H](O)[C@@H]1O QKFAFSGJTMHRRY-OCFLFPRFSA-M 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- PHZOWSSBXJXFOR-PTGZALFTSA-N sinigrin Chemical compound OC[C@H]1O[C@@H](S\C(CC=C)=N\OS(O)(=O)=O)[C@H](O)[C@@H](O)[C@@H]1O PHZOWSSBXJXFOR-PTGZALFTSA-N 0.000 description 1
- 235000017291 sinigrin Nutrition 0.000 description 1
- 239000000429 sodium aluminium silicate Substances 0.000 description 1
- 235000012217 sodium aluminium silicate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 235000019794 sodium silicate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 235000019976 tricalcium silicate Nutrition 0.000 description 1
- 229910021534 tricalcium silicate Inorganic materials 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B13/00—Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/281—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed
- A24B15/283—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by encapsulation of the chemical substances
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
- A24B15/301—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by aromatic compounds
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
- A24B15/302—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by natural substances obtained from animals or plants
- A24B15/303—Plant extracts other than tobacco
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
- A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
- A24B15/40—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having only oxygen or sulfur as hetero atoms
- A24B15/403—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having only oxygen or sulfur as hetero atoms having only oxygen as hetero atoms
- A24B15/406—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having only oxygen or sulfur as hetero atoms having only oxygen as hetero atoms in a five-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Agronomy & Crop Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacture Of Tobacco Products (AREA)
Abstract
Description
摂取可能な製品、例えば、無煙たばこ、噛みたばこ、スナッフ(snuff)、スヌース(snus)、溶解性たばこ、紙巻きたばこ、ツイスト、葉巻たばこおよびシガリロは、ニコチン、イソチオシアネートまたはイソチオシアネート前駆体の少なくとも1つ、およびミロシナーゼを含む。
マイクロ粒子およびナノ粒子に適した材料の例は、シリカ、アルミナ、チタニア、カーボンブラック、ケイ酸アルミニウム、ケイ酸カルシウム、ケイ酸マグネシウム、ケイ酸カリウム、ケイ酸ナトリウム、アルミノケイ酸ナトリウム、カルシウムアルミノケイ酸ナトリウム含有(sodium calcium aluminosilicate containing)、ケイ酸三カルシウム、シリカエアゲル(silica airgel)、タルク、酸化鉄、その他の金属酸化物の組み合わせである。
A549細胞を48ウェル培養プレートに3.0×104細胞/cm2の密度でプレーティングした。37℃での5分間のインキュベーションの後、0.05%トリプシンEDTAで細胞を解離させ、1:1の比率の標準培地で中和し、プレーティングの前に血球計を用いてカウントした。AITC、PETIC、チモキノン、またはレスベラトロールのいずれかの処理化合物を添加する前に、すべてのウェルを一晩静置した。すべての処理は、最初のプレーティングから24時間以内に行った。
Claims (29)
- ニコチン、および(a)イソチオシアネートまたはイソチオシアネート前駆体、(b)ミロシナーゼ、および(c)レスベラトロールの少なくとも1つを含む、摂取可能な製品。
- 無煙たばこ、噛みたばこ、スナッフ、スヌース、溶解性たばこ、紙巻きたばこ、ツイスト、葉巻たばこおよびシガリロのいずれか1つとして処方された、請求項1に記載の摂取可能な製品。
- 前記ニコチンの供給源として粉末状のたばこ葉をさらに含む、請求項1または請求項2に記載の摂取可能な製品。
- 前記ニコチンの供給源としてたばこ葉の抽出物をさらに含む、請求項1~3のいずれか一項に記載の摂取可能な製品。
- 前記イソチオシアネート前駆体の供給源として、ウォータークレス、ウォータークレス抽出物、ガーデンクレス、およびガーデンクレス抽出物のうちの少なくとも1つをさらに含む、請求項1~4のいずれか一項に記載の摂取可能な製品。
- 前記イソチオシアネートが合成されたもの(フェネチルイソチオシアネートまたはアリルイソチオシアネート)である、請求項1~5のいずれか一項に記載の摂取可能な製品。
- 前記ミロシナーゼの供給源としてマスタードシードおよびマスタードシード抽出物のうちの少なくとも1つをさらに含む、請求項1~6のいずれか一項に記載の摂取可能な製品。
- チモキノンをさらに含む、請求項1~7のいずれか一項に記載の摂取可能な製品。
- ブラッククミンシード抽出物をさらに含む、請求項1~8のいずれか一項に記載の摂取可能な製品。
- 合成ビタミンCをさらに含む、請求項1~9のいずれか一項に記載の摂取可能な製品。
- 前記レスベラトロールをさらに含む、請求項1~10のいずれか一項に記載の摂取可能な製品。
- 前記ニコチン、および(a)前記イソチオシアネートまたはイソチオシアネート前駆体、(b)前記ミロシナーゼ、および(c)前記レスベラトロールのそれぞれを含む、請求項1~11のいずれか一項に記載の摂取可能な製品。
- 前記ニコチンの供給源として粉末状のたばこ葉およびたばこ葉抽出物のうちの少なくとも1つと;
前記イソチオシアネート前駆体の供給源としてウォータークレス、ウォータークレス抽出物、ガーデンクレスおよびガーデンクレス抽出物のうちの少なくとも1つと;
前記ミロシナーゼの供給源としてマスタードシード抽出物と、
を含む、請求項1~12のいずれか一項に記載の摂取可能な製品。 - 合成イソチオシアネートをさらに含む、請求項13に記載の摂取可能な製品。
- チモキノンをさらに含む、請求項13に記載の摂取可能な製品。
- 合成ビタミンCをさらに含む、請求項13に記載の摂取可能な製品。
- レスベラトロールをさらに含む、請求項13に記載の摂取可能な製品。
- チモキノン、レスベラトロールおよび合成ビタミンCをさらに含む、請求項13に記載の摂取可能な製品。
- 前記ニコチンおよび前記イソチオシアネート前駆体、合成イソチオシアネートの少なくとも1つがカプセル化されている、請求項1~18のいずれか一項に記載の摂取可能な製品。
- 前記イソチオシアネート前駆体および合成イソチオシアネートがミセルおよびナノ粒子のうちの少なくとも1つにカプセル化されている、請求項1~19のいずれか一項に記載の摂取可能な製品。
- 前記イソチオシアネートおよび前駆体ならびに合成イソチオシアネートの少なくとも一部が、粉末状のたばこ葉およびたばこ葉抽出物のうちの少なくとも1つと直接接触している、請求項1~20のいずれか一項に記載の摂取可能な製品。
- 前記摂取可能な製品がフィルタを含む、請求項1~21のいずれか一項に記載の摂取可能な製品。
- 集団内のがんを予防または治療するが、前記集団の少なくとも一部のメンバーが、ニコチン、イソチオシアネートおよびイソチオシアネート前駆体のうちの少なくとも1つ、アミロシナーゼおよび合成イソチオシアネートを含む摂取可能な製品を利用できるようにする方法。
- 前記摂取可能な製品が、
前記ニコチンの供給源として粉末状のたばこ葉およびたばこ葉の抽出物のうちの少なくとも1つと;
前記イソチオシアネートの供給源としてウォータークレス、ウォータークレス抽出物、ガーデンクレスおよびガーデンクレス抽出物のうちの少なくとも1つと;合成イソチオシアネートと;
前記ミロシナーゼの供給源としてマスタードシード抽出物と、
を含む、請求項23に記載の方法。 - 前記摂取可能な製品がチモキノンをさらに含む、請求項23~24のいずれか一項に記載の方法。
- 前記摂取可能な製品がレスベラトロールをさらに含む、請求項23~25のいずれか一項に記載の方法。
- 前記摂取可能な製品がビタミンCをさらに含む、請求項23~26のいずれか一項に記載の方法。
- 前記摂取可能な製品を、無煙たばこ、噛みたばこ、スナッフ、スヌース、および溶解性たばこのうちの少なくとも1つとしてパッケージ化することをさらに含む、請求項23~27のいずれか一項に記載の方法。
- 前記摂取可能な製品を、紙巻きたばこ、ツイスト、葉巻たばこおよびシガリロのうちの少なくとも1つとしてパッケージ化することをさらに含む、請求項23~28のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962844846P | 2019-05-08 | 2019-05-08 | |
US62/844,846 | 2019-05-08 | ||
PCT/US2020/031849 WO2020227512A1 (en) | 2019-05-08 | 2020-05-07 | Use of isothiocyanate in smokeless tobacco products |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022539648A true JP2022539648A (ja) | 2022-09-13 |
JPWO2020227512A5 JPWO2020227512A5 (ja) | 2023-04-04 |
Family
ID=73046179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021566938A Pending JP2022539648A (ja) | 2019-05-08 | 2020-05-07 | 無煙たばこ製品におけるイソチオシアネートの使用 |
Country Status (6)
Country | Link |
---|---|
US (2) | US11730187B2 (ja) |
EP (1) | EP3955754A4 (ja) |
JP (1) | JP2022539648A (ja) |
CN (1) | CN114340410A (ja) |
SG (1) | SG11202112374YA (ja) |
WO (1) | WO2020227512A1 (ja) |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6348220B1 (en) | 1999-04-09 | 2002-02-19 | Rutgers, The State University Of New Jersey | Phenethylisothiocyanate nutraceutical compositions and methods |
ATE276676T1 (de) | 2001-10-22 | 2004-10-15 | Ivo Pera | Zusammensetzung zur reduzierung oder entwöhnung von nikotinabhängigkeit |
US6824796B2 (en) * | 2002-06-21 | 2004-11-30 | Access Business Group International Llc | Extraction of non-polar isothiocyanates from plants |
WO2006075330A2 (en) | 2005-01-12 | 2006-07-20 | S.U.L.V.E. Ltd. | Methods and pharmaceutical compositions useful for treating psoriasis |
US20080017207A1 (en) | 2006-07-18 | 2008-01-24 | Savipu Pharmaceuticals | Reduction of the Deleterious Effects of Tobacco Smoking by the Induction of Phase 2 Enzymes by Nerf2 |
CN101120948A (zh) | 2006-08-08 | 2008-02-13 | 普文英 | 一种具有化学保护、癌症预防和治疗用途的化合物组合物 |
DK2377413T3 (en) | 2007-07-23 | 2017-05-01 | Reynolds Tobacco Co R | Smokeless tobacco compositions and methods of treating tobacco for use therein |
US20100178286A1 (en) | 2007-07-27 | 2010-07-15 | Smith Walter P | Methods and compositions for reducing facial lines and wrinkles |
DE102008015101A1 (de) | 2008-03-19 | 2009-09-24 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Kauzusammensetzung und deren Verwendung |
CN101406319A (zh) | 2008-11-06 | 2009-04-15 | 广东神农烟科技术有限公司 | 白藜芦醇低害香烟 |
EP2544699A4 (en) | 2010-03-11 | 2013-08-21 | Health Research Inc | A NEW METHOD OF ADMINISTRATION AND USE OF ISOTHIOCYANATES FOR THE PROPHYLAXIS AND / OR TREATMENT OF BLADDER CANCER |
ES2647087T3 (es) | 2010-07-27 | 2017-12-19 | Flex Pharma, Inc. | Métodos y composiciones para prevenir y aliviar los calambres musculares y para la recuperación de la irritabilidad neuromuscular y de la fatiga después del ejercicio |
WO2012142511A2 (en) | 2011-04-15 | 2012-10-18 | Md Matrix Health Llc Dba Md Matrix Health Inc | Orthomolecular compositions and their use in stabilizing the extracellular matrix |
US8646461B2 (en) | 2011-12-14 | 2014-02-11 | Sentiens, Llc | Device and method for simulating chemosensation of smoking |
US20150068544A1 (en) * | 2013-09-09 | 2015-03-12 | R.J. Reynolds Tobacco Company | Smokeless tobacco composition incorporating a botanical material |
US9593077B2 (en) | 2013-11-18 | 2017-03-14 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
US9730916B2 (en) | 2014-02-27 | 2017-08-15 | Chang Gung Memorial Hospital, Keelung | Nutritional composition and method for improving heart failure |
WO2016100430A1 (en) | 2014-12-18 | 2016-06-23 | Csp Technologies, Inc. | Microbicidal agent for enhancing shelf stability |
EP3273948B1 (en) * | 2015-03-26 | 2020-02-12 | Patheon Softgels Inc. | Liquisoft capsules |
CN106690232B (zh) * | 2016-11-21 | 2021-03-30 | 青岛农业大学 | 一种富含异硫氰酸酯的蔬菜调味粉及其生产方法 |
CN106900962A (zh) | 2017-01-19 | 2017-06-30 | 上海王室环保科技有限公司 | 一种戒烟糖及其制备方法 |
CN109381499B (zh) * | 2017-08-07 | 2021-08-31 | 深圳福山生物科技有限公司 | 一种辣根组合物及其用途 |
-
2020
- 2020-05-07 WO PCT/US2020/031849 patent/WO2020227512A1/en unknown
- 2020-05-07 EP EP20801799.6A patent/EP3955754A4/en active Pending
- 2020-05-07 SG SG11202112374YA patent/SG11202112374YA/en unknown
- 2020-05-07 CN CN202080047886.9A patent/CN114340410A/zh active Pending
- 2020-05-07 US US16/868,830 patent/US11730187B2/en active Active
- 2020-05-07 JP JP2021566938A patent/JP2022539648A/ja active Pending
-
2023
- 2023-07-07 US US18/219,633 patent/US20230346002A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020227512A1 (en) | 2020-11-12 |
US20200352215A1 (en) | 2020-11-12 |
EP3955754A4 (en) | 2023-01-04 |
CN114340410A (zh) | 2022-04-12 |
US11730187B2 (en) | 2023-08-22 |
EP3955754A1 (en) | 2022-02-23 |
SG11202112374YA (en) | 2021-12-30 |
US20230346002A1 (en) | 2023-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
De Flora et al. | Modulation of cigarette smoke-related end-points in mutagenesis and carcinogenesis | |
Binnie et al. | Etiology of oral squamous cell carcinoma | |
Kırkıl et al. | Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease | |
ITPI20010014A1 (it) | Composto per filtri per sigarette,o altri articoli da fumo,a base di sostanze antiossidanti ed il filtro cosi'ottenuto | |
US20100108086A1 (en) | Tobacco and tobacco packaging material for preventing or reducing tobacco-associated injury in the aerodigestive tract of a subject | |
Sant’Ana et al. | Effect of piperlongumine during exposure to cigarette smoke reduces inflammation and lung injury | |
Varela-Lema et al. | Tobacco consumption and oral and pharyngeal cancer in a Spanish male population | |
Trybek et al. | The effect of n icotine on oral health | |
JP2022539648A (ja) | 無煙たばこ製品におけるイソチオシアネートの使用 | |
Sintija et al. | The oral microbiome of smokeless tobacco users in Latvia | |
OA20552A (en) | Use of isothiocyanate in smokeless tobacco products. | |
Patil et al. | Aqueous extract of tobacco induces mitochondrial potential dependent cell death and epithelial-mesenchymal transition in gingival epithelial cells | |
KR100553643B1 (ko) | 니코틴제거 효과가 있는 조성물 및 그 제조 방법 | |
Gupta et al. | Effect of cigarette smoke inhalation on benzo [a] pyrene-induced lung carcinogenesis in vitamin A deficiency in the rat | |
Arise et al. | Taurine and vitamin E protect against pulmonary toxicity in rats exposed to cigarette smoke | |
Ziyad | Smoking and oral health | |
Abro et al. | Smoking and Oral cancer | |
Jain et al. | Comparison of salivary flow rate and pH between healthy subjects and tobacco and areca nut chewers | |
Theophilus et al. | Toxicological evaluation of dry ice expanded tobacco | |
RU2346628C1 (ru) | Курительная смесь | |
Verma et al. | A Comparative Analyses of Dexamethasone and Neem Leaf Extract for Treating Cigarette-Smoke Induced Liver Injury in Swiss Mice | |
ALSSUM | PASSIVE SMOKING AND GINGIVAL PIGMENTATION. A LITERATURE REVIEW. | |
Sadykov | Smokeless tobacco-associated lesions of the oral cavity | |
Alzahrani et al. | The socioeconomic and cultural impact of tobacco and smoking in Saudi Arabia | |
Gul et al. | Self-perceived oral health status and cytomorphological changes in individuals with addictive oral habits: assessed by WHO oral health questionnaire for adults |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220901 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230327 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230327 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240528 |